drugset / Trial / NCT03811886
Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability of Natalizumab in children, adolescent and young adult patients with pulmonary metastatic osteosarcoma (pOS) and to assess clinical response associated with this treatment as well as overall survival.
Timeline
- Start
- 2024-12-01
- Primary completion
- 2025-12-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | natalizumab | Monoclonal antibody | 2 mg/kg | — |
| Subject | natalizumab | Monoclonal antibody | 3 mg/kg | — |
| Subject | natalizumab | Monoclonal antibody | 4 mg/kg | — |